Advertisement
The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol

Information

An Advocate’s Guide to HIV Research Terms in the Post-Placebo Era

May 16, 2017

There are more biomedical strategies available for HIV prevention than ever before. Daily oral PrEP is rolling out in countries around the world. Voluntary medical male circumcision continues to be scaled up. And antiretroviral treatment (ART) for people living with HIV is available “on demand” in many countries. Effective ART is good for people’s health and can help reduce the risk of passing on the virus.

At the same time, research is continuing. Today’s ARV-based prevention tools require high levels of adherence (e.g., taking a pill every day). Additional tools like a vaccine or a long-acting form of PrEP would be important additions.

Today’s trials have to test these new tools—and meet ethical standards by providing participants with the best available prevention package. This means something different now that PrEP is rolling out. This graphic and the accompanying lexicon showcase some of the new trial designs and terms used to talk about trial design.

Credit: AVAC

HIV Prevention Trial Lexicon

  • Active arm [of a trial] is the group of participants receiving a proven or experimental strategy. There can be one or more active arms in a trial. There can be an “active control” arm (see below) or an “active experimental arm”. The difference is whether the efficacy of the active strategy is known or not. Outcomes (like rates of HIV or rates of pregnancy) in people in the experimental active arm are compared to outcomes in people in the control arm.
  • Active control arm [of a trial] is usually a group of trial participants who are receiving a known effective strategy or intervention that participants in the experimental arm are not receiving. For example, in trials of long-acting injectable PrEP, people in the active control arm are receiving daily oral PrEP, a known effective strategy.
  • Blinded trials are ones in which the participants don’t know what they are receiving. A double-blinded trial is one in which neither the participants nor the trial team know which participants are receiving the experimental product and which ones are receiving something else—either a placebo or another product. Blinding protects against bias. If participants or trial staff know who is getting the active experimental product they might act differently. Participants who know they got the experimental product might take more risks if they believe the experimental product provides protection; people who got the placebo might use more condoms.
  • Control arm [of a trial] is the group of participants that are not receiving the experimental product or strategy. This group receives the same prevention package (see below) as the experimental arm.
  • Double-dummy double-blind trials are a way to compare two strategies that can’t be made to look identical, without revealing who’s receiving what. Imagine a trial seeking to compare an injection and a pill. They don’t look alike, right? In a double-dummy double-blind trial design, all of the participants would get both a pill and an injection. One group of participants would get an active pill and a dummy injection; the others would get an active injection and a dummy pill. Neither the staff nor the participants would know who had which active strategy.
  • Dummys are the same thing as placebos. A dummy version of an experimental product looks exactly like that product (e.g., vaccine, injection, infusion, pill or ring) except that it doesn’t have any active ingredient. Examples include a sugar pill or a saline injection or a ring without any drug inside it.
  • Non-inferiority trials are trials that are designed to show that a new method (Product A) works as well as a method that has previously been shown to work (Product B). If A doesn’t meet or exceed B’s effectiveness, it is considered inferior. This doesn’t mean it isn’t effective, just that it is not better than the existing product.
  • Open-label [trial] is a trial in which both participants and trial staff know who is receiving what. Trials of voluntary medical male circumcision were open-label in that trial staff and participants knew who had undergone the procedure immediately and who had been assigned to the delayed surgery arm.
  • Open-label extension (OLE) trial is a study that usually follows directly from an efficacy trial that showed the product was successful in reducing HIV risk. In OLEs, trial participants from both the active and placebo arm and, sometimes, members of their communities, get the chance to use the active product. Everyone knows what they are receiving and knows that the product worked in the efficacy trial.
  • A trial’s prevention package is the set of tools and services all participants receive, no matter which arm of the trial they are in. (In HIV prevention trials, all participants in both the control and active arms receive male and female condoms, counseling, HIV and STI testing and treatment and may receive other services like harm reduction, referrals for voluntary medical male circumcision, PrEP, etc.)
  • Superiority trials are trials that are designed to show that a method (Product A) is more effective than placebo, or sometimes, to show that a new method (product A) is more effective than an already-existing method (Product B). A superiority trial is designed to find out whether Product A is more effective than placebo (or Product B) in enrolled participants, and the trial makes every effort to ensure the products are used correctly and consistently.

  • Related Stories

    What's in Store for HIV Prevention in the Future?
    The Importance of Using Lube During Sex
    Quiz: Are You at Risk for HIV?
    10 Common Fears About HIV Transmission
    More Viewpoints on HIV Prevention



    This article was provided by AVAC: Global Advocacy for HIV Prevention. Visit AVAC's website to find out more about their activities and publications.
     

    No comments have been made.
     

    Add Your Comment:
    (Please note: Your name and comment will be public, and may even show up in
    Internet search results. Be careful when providing personal information! Before
    adding your comment, please read TheBody.com's Comment Policy.)

    Your Name:


    Your Location:

    (ex: San Francisco, CA)

    Your Comment:

    Characters remaining:

    Advertisement

    The content on this page is free of advertiser influence and was produced by our editorial team. See our advertising policy.